



7 March 2024

Sean Maloney
Senior Adviser, Listings Compliance
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000

By email: ListingsCompliancePerth@asx.com.au

Dear Sir

EMYRIA LIMITED: PRICE – QUERY

I refer to your letter to the Emyria Limited (“Emyria” or “the Company”) dated 7 March 2024 in relation to the change in price and trading volume of the Company’s securities.

Utilising the numbering in your letter, the Company responds as follows:

1. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.
2. Not applicable.
3. Recently, Emyria has attracted increased media attention. In particular, on 7 March 2024, the ABC ran a feature article and news story on Emyria’s innovative research programs focused on developing potential treatments for post-traumatic stress disorder (PTSD) (“the Coverage”). The Coverage highlighted Emyria's unique status as one of the few organisations in Australia approved by the Therapeutic Goods Administration (TGA) to use MDMA for therapeutic purposes.

Emyria believes the attention garnered by the Coverage contributed to the price and volume increase.

The Coverage included reference to a collaboration between Reach Wellness and Emyria.

Reach Wellness is a non-for-profit organisation focused on delivering solutions dedicated to the prevention, treatment and ongoing support of mental and physical health for first responders.

At the time of the Coverage, Emyria was progressing a non-binding memorandum of understanding with Reach Wellness which has not yet been finalised with them, with high level indicative terms, whereby should Reach Wellness be able to raise sufficient funds, it would fund a study proposed to be managed by Emyria for an initial cohort of

**myriad data.
individual care.**

Emyria Limited • ABN 96 625 085 734 • info@emyria.com •
Talk 1300 436 363 • D2, 661 Newcastle Street, Leederville WA 6007 •
PO Box 1442, West Leederville, Western Australia 6901 • [emyria.com](https://www.emyria.com)

up to 50 suitably qualified first responders utilising Emyria's MDMA-assisted therapy. Reach Wellness has initiated a fundraising campaign to cover all treatment and study related costs for an initial cohort of 50 first responders at an estimated cost of \$30,000 each.

While Emyria regards the collaboration to date to reflect a strong commitment towards a meaningful partnership, Emyria formed the view that the MOU under discussion was not material in consideration of section 7.10 of Guidance Note 8, which cautions against disclosing non-binding heads of agreements with material contractual terms that have yet to be agreed.

4. The Company confirms that it has at all times complied with, and continues to comply with, the ASX Listing Rules and in particular Listing Rule 3.1.
5. This response has been authorised and approved by the Board.

By order of the Board



Susan Park

Company Secretary



7 March 2024

Reference: 90234

Ms Susan Park
Company Secretary
Emyria Limited

By email:

Dear Ms Park

Emyria Limited ('EMD'): Price - Query

ASX refers to the following:

- A. The change in the price of EMD's securities from a low of \$0.048 to an intraday high of \$0.062 today.
- B. The significant increase in the volume of EMD's securities traded from yesterday to today.

Request for information

In light of this, ASX asks EMD to respond separately to each of the following questions and requests for information:

1. Is EMD aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is EMD relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in EMD's securities would suggest to ASX that such information may have ceased to be confidential and therefore EMD may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that EMD may have for the recent trading in its securities?
4. Please confirm that EMD is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that EMD's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of EMD with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **5:00 PM AWST Thursday, 7 March 2024**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall

within the exceptions mentioned in Listing Rule 3.1A, EMD's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require EMD to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in EMD's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in EMD's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to EMD's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that EMD's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Yours sincerely

ASX Compliance